ZEOX
Zeo ScientifiX, Inc.
Price Chart
Latest Quote
$2.37
Current Price| Previous Close | $2.57 |
| Open | $2.57 |
| Day High | $2.57 |
| Day Low | $2.37 |
| Volume | 3,153 |
Stock Information
| Shares Outstanding | 7.61M |
| Total Debt | $353K |
| Cash Equivalents | $221K |
| Revenue | $5.20M |
| Net Income | $-5.52M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $18.05M |
| EPS (TTM) | $-0.80 |
| Exchange | OQB |
đ Custom Metrics & Score
Score: 13/42| Debt to Equity | -0.25 |
| Debt to Earnings | 0.08 |
| Current Ratio | 0.33 |
| Quick Ratio | 0.09 |
| Avg Revenue Growth | -4.98% |
| Profit Margin | -106.19% |
| Return on Equity | 387.98% |
| Avg FCF Growth | -20.36% |
| FCF Yield | -4.11% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $2.37 | 3,153 |
| 2026-01-30 | $2.67 | 6,000 |
| 2026-01-29 | $2.58 | 1,500 |
| 2026-01-28 | $2.64 | 800 |
| 2026-01-27 | $2.57 | 11,600 |
| 2026-01-26 | $2.74 | 13,900 |
| 2026-01-23 | $2.74 | 20,800 |
| 2026-01-22 | $2.69 | 500 |
| 2026-01-21 | $2.64 | 2,800 |
| 2026-01-20 | $2.60 | 9,700 |
| 2026-01-16 | $2.70 | 1,300 |
| 2026-01-15 | $2.62 | 2,400 |
| 2026-01-14 | $2.66 | 700 |
| 2026-01-13 | $2.70 | 3,000 |
| 2026-01-12 | $2.55 | 600 |
| 2026-01-09 | $2.60 | 19,600 |
| 2026-01-08 | $2.80 | 2,300 |
| 2026-01-07 | $2.88 | 1,700 |
| 2026-01-06 | $2.89 | 2,500 |
| 2026-01-05 | $2.79 | 14,600 |
About Zeo ScientifiX, Inc.
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, osteoarthritis,and traumatic brain injury. The company also provides Patient Pure X, an autologous biologic, that helps reduce inflammation and promote tissue healing and regeneration. In addition, it develops and distributes products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications; ZEO GROWX, ZEO HAIR GROW, and ZEO GROW BOOST, a serum comprised of hair growth stimulants for follicle stimulation. The company was formerly known as Organicell Regenerative Medicine, Inc. and changed its name to Zeo ScientifiX, Inc. in February 2024. Zeo ScientifiX, Inc. was incorporated in 2011 and is based in Davie, Florida.
đ° Latest News
No news articles available at the moment. Check back later for updates on ZEOX.
Income Statement (Annual)
Revenue
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $931,000 | $844,000 | $508,000 | $753,534 |
| Cost Of Revenue | $931,000 | $844,000 | $508,000 | $753,534 |
| Total Revenue | $5,199,000 | $4,620,000 | $4,558,000 | $6,491,008 |
| Operating Revenue | $5,199,000 | $4,620,000 | $4,558,000 | $6,491,008 |
Expenses
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Interest Expense | $98,000 | $92,000 | $431,000 | $398,260 |
| Total Expenses | $10,585,000 | $9,939,000 | $11,326,000 | $15,333,968 |
| Other Income Expense | $-37,000 | $706,000 | $212,000 | $344,663 |
| Other Non Operating Income Expenses | $-35,000 | $441,000 | $-29,000 | $344,663 |
| Net Non Operating Interest Income Expense | $-98,000 | $-92,000 | $-431,000 | $-398,260 |
| Interest Expense Non Operating | $98,000 | $92,000 | $431,000 | $398,260 |
| Operating Expense | $9,654,000 | $9,095,000 | $10,818,000 | $14,580,434 |
| General And Administrative Expense | $9,654,000 | $9,095,000 | $10,818,000 | $14,580,434 |
Income & Earnings
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-5,521,000 | $-4,705,000 | $-6,987,000 | $-8,896,557 |
| Net Interest Income | $-98,000 | $-92,000 | $-431,000 | $-398,260 |
| Normalized Income | $-5,519,000 | $-4,970,000 | $-7,228,000 | $-8,896,557 |
| Net Income From Continuing And Discontinued Operation | $-5,521,000 | $-4,705,000 | $-6,987,000 | $-8,896,557 |
| Total Operating Income As Reported | $-5,386,000 | $-5,319,000 | $-6,768,000 | $-8,842,960 |
| Net Income Common Stockholders | $-5,521,000 | $-4,705,000 | $-6,987,000 | $-8,896,557 |
| Net Income | $-5,521,000 | $-4,705,000 | $-6,987,000 | $-8,896,557 |
| Net Income Including Noncontrolling Interests | $-5,521,000 | $-4,705,000 | $-6,987,000 | $-8,896,557 |
| Net Income Continuous Operations | $-5,521,000 | $-4,705,000 | $-6,987,000 | $-8,896,557 |
| Pretax Income | $-5,521,000 | $-4,705,000 | $-6,987,000 | $-8,896,557 |
| Special Income Charges | $-2,000 | $265,000 | $241,000 | $0 |
| Operating Income | $-5,386,000 | $-5,319,000 | $-6,768,000 | $-8,842,960 |
| Gross Profit | $4,268,000 | $3,776,000 | $4,050,000 | $5,737,474 |
Per Share Metrics
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Diluted EPS | - | $-0.74 | $-0.99 | $-1.56 |
| Basic EPS | - | $-0.74 | $-0.99 | $-1.56 |
Other
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,348,000 | $-4,804,000 | $-6,311,000 | $-8,165,789 |
| Total Unusual Items | $-2,000 | $265,000 | $241,000 | $0 |
| Total Unusual Items Excluding Goodwill | $-2,000 | $265,000 | $241,000 | $0 |
| Reconciled Depreciation | $73,000 | $74,000 | $486,000 | $332,508 |
| EBITDA (Bullshit earnings) | $-5,350,000 | $-4,539,000 | $-6,070,000 | $-8,165,789 |
| EBIT | $-5,423,000 | $-4,613,000 | $-6,556,000 | $-8,498,297 |
| Diluted NI Availto Com Stockholders | $-5,521,000 | $-4,705,000 | $-6,987,000 | $-8,896,557 |
| Write Off | $0 | $-176,000 | $100,000 | $0 |
| Restructuring And Mergern Acquisition | $2,000 | $0 | - | - |
| Selling General And Administration | $9,654,000 | $9,095,000 | $10,818,000 | $14,580,434 |
| Other Gand A | $9,654,000 | $9,095,000 | $10,818,000 | $14,580,434 |
| Diluted Average Shares | - | $6,336,392 | $7,028,638 | $5,688,230 |
| Basic Average Shares | - | $6,336,392 | $7,028,638 | $5,688,230 |
| Gain On Sale Of Ppe | - | $0 | $341,000 | $0 |
| Other Special Charges | - | $-89,000 | - | - |
| Tax Provision | - | - | - | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-1,423,000 | $-1,653,000 | $-1,241,000 | $1,888,604 |
| Total Assets | $1,527,000 | $1,643,000 | $2,782,000 | $6,200,688 |
| Total Non Current Assets | $569,000 | $478,000 | $580,000 | $1,834,447 |
| Current Assets | $958,000 | $1,165,000 | $2,202,000 | $4,366,241 |
| Prepaid Assets | $279,000 | $79,000 | $106,000 | $173,152 |
| Inventory | $423,000 | $232,000 | $310,000 | $248,510 |
| Receivables | $35,000 | $197,000 | $30,000 | $191,482 |
| Accounts Receivable | $35,000 | $194,000 | $18,000 | $55,110 |
| Cash Cash Equivalents And Short Term Investments | $221,000 | $657,000 | $1,756,000 | $3,753,097 |
| Cash And Cash Equivalents | $221,000 | $657,000 | $1,756,000 | $3,753,097 |
| Cash Financial | $221,000 | $657,000 | $1,756,000 | $3,753,097 |
| Non Current Prepaid Assets | - | $0 | $7,000 | $39,936 |
| Other Receivables | - | $3,000 | $12,000 | $7,433 |
Debt
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Net Debt | $22,000 | $23,000 | - | - |
| Total Debt | $353,000 | $693,000 | $693,000 | $1,038,194 |
| Long Term Debt And Capital Lease Obligation | $77,000 | $8,000 | $13,000 | $248,928 |
| Current Debt And Capital Lease Obligation | $276,000 | $685,000 | $680,000 | $789,266 |
| Current Debt | $243,000 | $680,000 | $657,000 | $563,111 |
| Other Current Borrowings | $243,000 | $680,000 | $657,000 | - |
Liabilities
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $2,950,000 | $3,296,000 | $4,023,000 | $4,312,084 |
| Total Non Current Liabilities Net Minority Interest | $77,000 | $8,000 | $13,000 | $248,928 |
| Current Liabilities | $2,873,000 | $3,288,000 | $4,010,000 | $4,063,156 |
| Other Current Liabilities | $19,000 | - | - | $674,462 |
| Current Deferred Liabilities | $598,000 | $884,000 | $497,000 | $0 |
| Payables And Accrued Expenses | $1,980,000 | $1,719,000 | $2,833,000 | $2,599,428 |
| Interest Payable | $1,000 | $5,000 | - | - |
| Payables | $1,312,000 | $1,047,000 | $2,080,000 | $1,848,964 |
| Other Payable | $1,312,000 | $1,047,000 | $1,859,000 | $1,628,067 |
| Current Notes Payable | - | - | $0 | $563,111 |
| Accounts Payable | - | - | - | $2,378,531 |
Equity
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Common Stock Equity | $-1,423,000 | $-1,653,000 | $-1,241,000 | $1,888,604 |
| Total Equity Gross Minority Interest | $-1,423,000 | $-1,653,000 | $-1,241,000 | $1,888,604 |
| Stockholders Equity | $-1,423,000 | $-1,653,000 | $-1,241,000 | $1,888,604 |
| Retained Earnings | $-67,734,000 | $-62,213,000 | $-57,508,000 | $-50,521,306 |
Other
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $6,551,094 | $6,344,817 | $7,283,483 | $7,395,631 |
| Share Issued | $6,551,094 | $6,344,817 | $7,283,483 | $7,395,631 |
| Tangible Book Value | $-1,423,000 | $-1,653,000 | $-1,241,000 | $1,888,604 |
| Invested Capital | $-1,180,000 | $-973,000 | $-584,000 | $2,451,715 |
| Working Capital | $-1,915,000 | $-2,123,000 | $-1,808,000 | $303,085 |
| Capital Lease Obligations | $110,000 | $13,000 | $36,000 | $475,083 |
| Total Capitalization | $-1,423,000 | $-1,653,000 | $-1,241,000 | $1,888,604 |
| Additional Paid In Capital | $66,304,000 | $60,554,000 | $56,260,000 | $52,402,514 |
| Capital Stock | $7,000 | $6,000 | $7,000 | $7,396 |
| Common Stock | $7,000 | $6,000 | $7,000 | $7,396 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $77,000 | $8,000 | $13,000 | $248,928 |
| Current Deferred Revenue | $598,000 | $884,000 | $497,000 | $0 |
| Current Capital Lease Obligation | $33,000 | $5,000 | $23,000 | $226,155 |
| Current Accrued Expenses | $668,000 | $672,000 | $753,000 | $750,464 |
| Net PPE | $569,000 | $478,000 | $573,000 | $1,794,511 |
| Accumulated Depreciation | $-365,000 | $-292,000 | $-222,000 | $-439,654 |
| Gross PPE | $934,000 | $770,000 | $795,000 | $2,234,165 |
| Other Properties | $934,000 | $770,000 | $795,000 | $1,281,352 |
| Finished Goods | $215,000 | $68,000 | $156,000 | $163,414 |
| Raw Materials | $208,000 | $164,000 | $154,000 | $85,096 |
| Dueto Related Parties Current | - | $0 | $221,000 | $220,897 |
| Leases | - | - | $0 | $925,932 |
| Machinery Furniture Equipment | - | - | $0 | $26,881 |
| Properties | - | - | $0 | $0 |
| Duefrom Related Parties Current | - | - | $0 | $128,939 |
| Construction In Progress | - | - | - | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Free Cash Flow | $-741,000 | $-1,450,000 | $-2,223,000 | $-3,990,583 |
Operating Activities
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-718,000 | $-1,450,000 | $-2,197,000 | $-3,165,840 |
| Cash Flow From Continuing Operating Activities | $-718,000 | $-1,450,000 | $-2,197,000 | $-3,165,840 |
| Operating Gains Losses | - | - | $-341,000 | - |
Investing Activities
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Capital Expenditure | $-23,000 | - | $-26,000 | $-824,743 |
| Investing Cash Flow | $-23,000 | $-45,000 | $615,000 | $-824,743 |
| Cash Flow From Continuing Investing Activities | $-23,000 | $-45,000 | $615,000 | $-824,743 |
| Net Other Investing Changes | - | - | $741,000 | - |
Financing Activities
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $0 | $-80,000 | $-500,000 | $0 |
| Issuance Of Capital Stock | $300,000 | $500,000 | $100,000 | $7,270,000 |
| Financing Cash Flow | $305,000 | $396,000 | $-415,000 | $7,635,110 |
| Cash Flow From Continuing Financing Activities | $305,000 | $396,000 | $-415,000 | $7,635,110 |
| Net Common Stock Issuance | $300,000 | $420,000 | $-400,000 | $7,270,000 |
| Common Stock Issuance | $300,000 | $500,000 | $100,000 | $7,270,000 |
| Net Other Financing Charges | - | - | - | $250,000 |
Other
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-45,000 | $-24,000 | $-1,245,000 | $-424,890 |
| Interest Paid Supplemental Data | $20,000 | $68,000 | $67,000 | $78,625 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $221,000 | $657,000 | $1,756,000 | $3,753,097 |
| Beginning Cash Position | $657,000 | $1,756,000 | $3,753,000 | $108,570 |
| Changes In Cash | $-436,000 | $-1,099,000 | $-1,997,000 | $3,644,527 |
| Proceeds From Stock Option Exercised | $50,000 | $0 | - | - |
| Common Stock Payments | $0 | $-80,000 | $-500,000 | $0 |
| Net Issuance Payments Of Debt | $-45,000 | $-24,000 | $-15,000 | $115,110 |
| Net Long Term Debt Issuance | $-45,000 | $-24,000 | $-115,000 | $115,110 |
| Long Term Debt Payments | $-45,000 | $-24,000 | $-115,000 | $-424,890 |
| Net Investment Purchase And Sale | $0 | $-45,000 | $-100,000 | $0 |
| Purchase Of Investment | $0 | $-45,000 | $-100,000 | $0 |
| Net PPE Purchase And Sale | $-23,000 | $0 | $-26,000 | $-824,743 |
| Purchase Of PPE | $-23,000 | $0 | $-26,000 | $-824,743 |
| Change In Working Capital | $-140,000 | $-528,000 | $790,000 | $1,394,416 |
| Change In Other Working Capital | $-286,000 | $387,000 | $497,000 | $-9,575 |
| Change In Payables And Accrued Expense | $200,000 | $-851,000 | $233,000 | $1,692,612 |
| Change In Payable | $200,000 | $-851,000 | $233,439 | $1,035,609 |
| Change In Account Payable | $200,000 | $-851,000 | $233,439 | $1,035,609 |
| Change In Prepaid Assets | $-25,000 | $34,000 | $102,000 | $-118,259 |
| Change In Inventory | $-191,000 | $78,000 | $-62,000 | $-51,138 |
| Change In Receivables | $162,000 | $-176,000 | $20,000 | $-119,224 |
| Changes In Account Receivables | $159,000 | $-185,000 | $37,000 | $17,148 |
| Other Non Cash Items | $41,000 | $68,000 | $468,000 | $271,752 |
| Stock Based Compensation | $4,693,000 | $3,853,000 | $3,209,000 | $3,916,590 |
| Asset Impairment Charge | $136,000 | $-212,000 | $178,000 | $-184,549 |
| Depreciation Amortization Depletion | $73,000 | $74,000 | $486,000 | $332,508 |
| Depreciation And Amortization | $73,000 | $74,000 | $486,000 | $332,508 |
| Depreciation | $73,000 | $74,000 | $106,000 | - |
| Net Income From Continuing Operations | $-5,521,000 | $-4,705,000 | $-6,987,000 | $-8,896,557 |
| Issuance Of Debt | - | $0 | $1,230,000 | $540,000 |
| Net Short Term Debt Issuance | - | $0 | $100,000 | - |
| Short Term Debt Payments | - | $0 | $-1,130,000 | - |
| Short Term Debt Issuance | - | $0 | $1,230,000 | - |
| Amortization Cash Flow | - | $0 | $380,000 | - |
| Amortization Of Intangibles | - | $0 | $380,000 | - |
| Long Term Debt Issuance | - | - | $1,229,400 | $540,000 |
| Change In Accrued Expense | - | - | $0 | $657,003 |
| Provisionand Write Offof Assets | - | - | - | $27,500 |